Azhar Ayesha, Taimuri Muskan A, Oduoye Malik Olatunde, Sumbal Anusha, Sheikh Ayesha, Iqbal Amna, Ikram Areeba, Waqar Eisha
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
The Medical Research Circle, Gisenyi, Goma, Democratic Republic of Congo.
Ann Med Surg (Lond). 2024 Jun 26;86(9):5292-5298. doi: 10.1097/MS9.0000000000002322. eCollection 2024 Sep.
Dry eye disease (DED) or keratoconjunctivitis sicca (KCS) is a multifactorial disease that classically develops due to the hyperosmolarity of the tear film. Categorically divided into two types, based on decreased production and increased evaporation of the tear film, DED begins with a spectrum of nonspecific symptoms like pruritus, redness, burning and discomfort, progressively leading to stringy mucus eye discharge, photophobia, twitching, visual fluctuations, and punctate epithelial lesions. This disease has numerous treatment options, including medications, artificial tear inducers, and surgical manoeuvres that prevent water loss from the tear film. However, each of these treatment options has its limitations. The Food and Drug Administration (FDA) has approved another intervention, Meibo (perfluorohexyloctane), as a choice of management for dry eye disease. With its shielding action on the ocular surface, Meibo (perfluorohexyloctane) reduces desiccation stress-induced ocular damage, making it highly specific for treating DED. Available in an eye drop formulation of perfluorohexyloctane (PFHO), these drops can reduce saline evaporation by up to 80%. The methods we used for this analysis are literature searches from PubMed, Medline and Google Scholar. This study aims to scour varying differentials of DED, its aetiology, general interventions, the latest refinements, and clinical efficacy, safety, and trials associated with Meibo (perfluorohexyloctane) in the management of DED.
干眼症（DED）或角结膜干燥症（KCS）是一种多因素疾病，通常由于泪膜高渗而发病。根据泪膜分泌减少和蒸发增加，干眼症明确分为两种类型，其初期表现为一系列非特异性症状，如瘙痒、发红、灼烧感和不适感，进而逐渐发展为丝状黏液性眼部分泌物、畏光、抽搐、视力波动和点状上皮病变。这种疾病有多种治疗选择，包括药物治疗、人工泪液诱导剂以及防止泪膜水分流失的手术操作。然而，这些治疗选择都有其局限性。美国食品药品监督管理局（FDA）已批准另一种干预措施——美泊（全氟己基辛烷），作为干眼症的一种治疗选择。美泊（全氟己基辛烷）通过对眼表的保护作用，减轻干燥应激引起的眼部损伤，使其对治疗干眼症具有高度特异性。其全氟己基辛烷（PFHO）滴眼剂剂型可使盐分蒸发减少高达80%。我们用于该分析的方法是从PubMed、Medline和谷歌学术进行文献检索。本研究旨在探究干眼症的不同鉴别诊断、病因、一般干预措施、最新进展，以及美泊（全氟己基辛烷）治疗干眼症的临床疗效、安全性和相关试验。
